Navigation Links
CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
Date:4/24/2008

LAS VEGAS, April 24 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBTE) has entered into an agreement with Mr. Phillip Frey Jr. to form Cardio Derma Clinical Partners (CDCP), an R&D Partnership. Mr. Frey, as sponsor and general partner, will fund a minimum of $1,000,000 and up to $5,000,000 of the clinical development of CVBT's wound healing drug candidate.

"R&D Partnerships have been successfully used in the past by some of today's biggest names in biotechnology to fund drug development. Many investors in these R&D Partnerships realized income tax advantages and have earned outstanding returns on their investments," said Mr. Phillip Frey Jr. He continued, "CVBT and Cardio Derma Clinical Partners are going back to these basics in an effort to advance this drug candidate."

CDCP will engage CVBT in a development agreement to conduct its wound healing clinical trial. CVBT will pay a royalty to CDCP of 10% of revenues or other moneys received from the commercialization of the drug candidate up to a maximum of ten times (10x) the funded amount of the development agreement in return for the intellectual property created. Additionally, CDCP will acquire warrants, the number of which is dependent upon the funded amount of the development agreement, to purchase CVBT common shares at an exercise price of $1.00 per share with a term of five years. Daniel C. Montano, CVBT's President and CEO, has agreed to personally provide the individual partners of CDCP a Put to Mr. Montano for their interest in CDCP equal to 200% of their investment in CDCP less distributions paid from CDCP commencing 36 months and ending 60 months after their investment in CDCP.

CVBT's pipeline includes drug candidates for the treatment of various cardiovascular diseases, including severe coronary heart disease, diabetic wounds, peripheral arterial disease, chronic back pain and bone repair. "We anticipate knowing whether we will meet the endpoints of the Phase II coronary heart disease and wound healing trials in approximately 12 to 18 months," said Mr. Montano. He continued, "Conducting FDA clinical trials is expensive and requires timely access to capital. The disruptions in the financial market over the last six months have made access to capital more difficult. Given the current market, we believe that structuring R&D Partnerships tailored to the circumstances of individual drug candidates and partnerships provides a sensible financing alternative for funding our clinical trials."

According to Mickael A. Flaa, CVBT's Chief Financial Officer, "The ability to attract capital in this form is a major milestone in the financial growth and maturity of CVBT." Mr. Flaa continued, "This financing vehicle is very attractive to both the Company and its shareholders due to assumption of risk of loss by the R&D Partnership and the modest dilution resulting from the financing. The R&D Partnership concept is the type of financing alternative that CVBT will focus on for other drug candidates in the pipeline until the financial markets are receptive to timely, cost effective access to capital for CVBT common stock."

About Mr. Phillip Frey Jr.

Mr. Phillip Frey Jr. is the retired Chairman, CEO, and President of Microsemi Corporation (MSCC). He was Chairman of Microsemi's Board of Directors from 1986 through 2002 and a member of the Board of Directors since 1973. He also served as its President and CEO from 1971 to December 2000. Microsemi Corporation designs, manufactures, and markets analog and mixed-signal integrated circuits (ICs) and semiconductors. Since retiring from Microsemi Corporation, Mr. Frey has focused his business endeavors in real estate investments and has been a major angel investor in numerous new ventures in the medical and electronics areas.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetes and in patients suffering from peripheral artery disease of the legs. An additional proof-of-concept study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information please visit http://www.cvbt.com.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Media Contact:

Allison Lipson

CardioVascular BioTherapeutics, Inc.

(702) 839-7200

alipson@cvbt.com


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
2. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
3. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
4. HealthAware Introduces Its VascularAware Cardiovascular Disease Module
5. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
6. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
7. VIA Pharmaceuticals Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Informations Therapeutic Area Partnerships Conference
8. Amarin Announces Initiation of Cardiovascular Development Strategy
9. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
10. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
11. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Ky. , Feb. 10, 2016 NX ... utilizing its proprietary NeXosome® technology for early warning ... of its most recent study by Dr. ... at the Society for Maternal Fetal Medicine,s (SMFM) annual ... GA, February 1-6 th , 2016.  The presentation reported ...
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., ... for fast growing biotech companies, announced today the ... Procurement Strategic Advisor. Jim brings nearly 25 years ... and procurement, having spent nearly two decades in ... Chain/Logistics and Procurement at Genzyme and, most recently ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... Testing (PROMPT), a research registry built on the secure online PatientCrossroads platform, has ... More than 1,600 participants have joined the PROMPT study, which seeks to advance ...
(Date:2/9/2016)... ... , ... With a presidential election in November and the future of U.S. ... over 500 top healthcare leaders for a night and day of debates and discussions ... students of the University of Pennsylvania’s Wharton School, will be held February 18 – ...
Breaking Biology Technology:
(Date:2/1/2016)... 1, 2016  Today, the first day of American ... to develop a first of its kind workplace health ... Watson. In the first application of Watson ... IBM ), and Welltok will create a new offering ... cognitive analytics, delivered on Welltok,s health optimization platform. The ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/20/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce the attainment of record-setting corporate ... of the company,s laser focus on (and growing international ... comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... growth achievements in 2015 include: , Record ...
Breaking Biology News(10 mins):